[The use of neoadjuvant selective intra-arterial polychemotherapy and its modifier verapamil in the combined treatment of colorectal cancer]. / Primenenie neoad'iuvantnoi selektivnoi vnutriarterial'noi polikhimioterapii i ee modifikatora verapamila v kombinirovannom lechenii kolorektal'nogo raka.

After combined treatment of 74 patients for colorectal cancer using preoperative neoadjuvant intraarterial selective polychemotherapy (IAPCT) three-year survival index have constituted (77.0 +/- 5.2)%, the cancer recurrence have occurred in (10.8 +/- 2.8)%, distant metastases were revealed in (17.5 +/- 4.2)%. Using verapamil as a IAPCT modifier in 54 patient three-year survival have increased by 11.8%, the frequency of distant metastases occurrence have reduced by 10.1%.

Neoadjuvant intra-arterial polychemotherapy of locally advanced rectal cancer.

In order to evaluate the usefulness of pre-operative intra-arterial selective polychemotherapy (PIASP), we carried out a retrospective study of 107 patients (65 males, 42 females) with locally advanced rectal cancer (LARC) (pT3-4 N0-1 M0), who were treated between 1988 and 1991. Fifty-two patients (MG) underwent PIASP (Adriablastin 60-90 mg, fluorouracil 3-4 g) with subsequent radical surgery. Fifty-five patients (R0) received surgery alone. Angiographic findings after PIASP showed approximately 50-70% reduction in the vascular network in the tumour and surrounding tissues. A post-operative morphological study confirmed the considerable tumour dystrophy, necrobiosis and necrosis. Comparative statistical analysis in two patient groups showed that overall 5-year survival was significantly better in MG (64.76 +/- 1.85%) than in R0 (38.23 +/- 1.74%; chi 2 = 9.1; P < 0.05). A similar situation was observed in all research subgroups: T3 N0 M0 (MG, 85.71 +/- 3.29% and R0, 65.63 +/- 2.85%; chi 2 = 2.61; P < 0.05); T3 N1 M0 (MG, 47.06 +/- 4.68% and R0, 0.0, chi 2 = 14.37; P < 0.05); T4 N0-1 M0 (MG, 8.57 +/- 4.29% and R0, 0.0, chi 2 = 2.09; P < 0.05). Significantly better 5-year survival rates were seen in MG than in R0 with the medial cellular differentiation in carcinoma (77.42 +/- 2.98% and 36.23 +/- 2.41%, chi 2 = 9.81; P < 0.05, respectively), the most frequent histological tumour structures. There is a trend for improved 5-year survival in low differentiation carcinoma (MG, 47.62 + 5.29% and R0, 35.29 +/- 4.37%, chi 2 = 0.28, P > 0.05). The MG group showed eight local relapses of disease (15.38%), while the R0 group showed 21 (38.1%), the MG group demonstrated 12 distant metastasis (23.07%) while R0 demonstrated 19 (34.54%), the median relapse-free survival was 101.6 weeks in MG and 74.45 weeks in R0. The use of the combined PIASP with subsequent surgery treatment of patients with LARC allows a better prognosis than does surgery alone.

[A preliminary assessment of the efficacy of anticancer measures in malignant stomach neoplasms]. / Predvaritel'naia otsenka éffektivnosti protivorakovykh meropriiatii pri zlokachestvennykh novoobrazovaniiakh zheludka.

Anticancer prophylactic and treatment measures are approved initially among small populations contingents and, hence, their results are not essentially effecting demographic values. Changes of the state of selected contingents are evaluated by means of lethality or survival values. On the example of gastric cancer patients survival, the authors determine the period of observation necessary for preliminary evaluation of the efficiency of anticancer measures. During 5 years there was no clear change of survival of patients with gastric cancer of stage I-II (P > 0.05). The duration of the period of statistically valid reduction (P < 0.001) of the survival of patients with gastric cancer (stage III-IV) was two years. Thus, changes of the level of two year survival in patients advanced gastric cancer under the effect of anticancer measures may be used for express-evaluation of these measures.